Altimmune (ALT) Set to Announce Quarterly Earnings on Thursday

Altimmune (NASDAQ:ALT) is set to post its quarterly earnings results before the market opens on Thursday, May 9th. Analysts expect Altimmune to post earnings of ($0.36) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Wednesday, March 27th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.02. Altimmune had a negative return on equity of 44.77% and a negative net margin of 20,780.75%. The business had revenue of $0.04 million during the quarter. On average, analysts expect Altimmune to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Altimmune Price Performance

Shares of ALT stock opened at $7.27 on Wednesday. The business’s fifty day moving average price is $9.03 and its 200 day moving average price is $7.77. The firm has a market capitalization of $515.37 million, a PE ratio of -4.41 and a beta of 0.22. Altimmune has a 1-year low of $2.09 and a 1-year high of $14.84.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ALT shares. The Goldman Sachs Group assumed coverage on shares of Altimmune in a research note on Wednesday, January 24th. They set a “neutral” rating and a $13.00 price target on the stock. HC Wainwright dropped their target price on shares of Altimmune from $15.00 to $12.00 and set a “buy” rating for the company in a report on Monday, April 1st. B. Riley reissued a “buy” rating and set a $20.00 price target on shares of Altimmune in a research note on Thursday, March 28th. Finally, Guggenheim downgraded Altimmune from a “buy” rating to a “neutral” rating in a research note on Monday, April 29th.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.